Success Metrics

Active Trials
6(67%)

Phase Distribution

Ph phase_1
1
11%
Ph not_applicable
2
22%
Ph early_phase_1
6
67%

Phase Distribution

7

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Early Phase 1First-in-human
6(66.7%)
Phase 1Safety & dosage
1(11.1%)
N/ANon-phased studies
2(22.2%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

6

trials recruiting

Total Trials

9

all time

Status Distribution
Active(6)
Other(3)

Detailed Status

Recruiting5
unknown3
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
6
Success Rate
N/A
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 16 (66.7%)
Phase 11 (11.1%)
N/A2 (22.2%)

Trials by Status

unknown333%
active_not_recruiting111%
recruiting556%

Recent Activity

6 active trials
Showing 5 of 9
recruitingearly_phase_1

Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases

NCT04504526
recruitingnot_applicable

Application of 68Ga-Pentixafor PET/CT in Primary Aldosteronism and Pre-postoperative of SAAE

NCT05188872
recruitingearly_phase_1

In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET

NCT05093335
recruitingphase_1

Diagnostic Value of CXCR4-targeted PET/CT in ACTH-dependent and Independent Cushing's Syndrome

NCT07350707
active_not_recruitingearly_phase_1

Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors

NCT03335670
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT04504526Early Phase 1

Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases

Recruiting
NCT05188872Not Applicable

Application of 68Ga-Pentixafor PET/CT in Primary Aldosteronism and Pre-postoperative of SAAE

Recruiting
NCT05093335Early Phase 1

In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET

Recruiting
NCT07350707Phase 1

Diagnostic Value of CXCR4-targeted PET/CT in ACTH-dependent and Independent Cushing's Syndrome

Recruiting
NCT03335670Early Phase 1

Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors

Active Not Recruiting
NCT05255926Not Applicable

CXCR4-targeted PET/CT Imaging in Hematological Malignancies

Recruiting
NCT06086327Early Phase 1

Application of 68Ga-Pentixafor PET/CT for Thymoma

Unknown
NCT05364177Early Phase 1

68Ga-pentixather and 68Ga-pentixafor PET/CT in Multiple Myeloma

Unknown
NCT03436342Early Phase 1

Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma

Unknown

All 9 trials loaded

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
9